© Reuters.
WEXFORD, Pa. – Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), a biopharmaceutical company, announced today an expansion of its exclusive license agreement with the University of Pittsburgh. The amendment includes autoimmune diseases in the development of its SNAP-CAR T and SNAP-CAR NK cell therapies, originally focused on oncology.
This strategic move leverages recent research suggesting the potential of CD19-targeting chimeric antigen receptor (CAR) T cells, initially used in B cell malignancies, to also address autoimmune diseases by targeting autoreactive B cells. The expansion aligns with a broader vision to explore revolutionary treatments for a range of autoimmune conditions such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis.
Dave Mehalick, President and CEO of Coeptis Therapeutics, expressed the company’s dedication to developing these technologies for oncology and the immense potential they hold for the treatment of autoimmune diseases. The SNAP-CAR platform’s adaptability to target multiple antigens could place Coeptis at the forefront of next-generation therapies.
The autoimmune disease market is significant, with more than 100 conditions affecting 1 in 5 Americans, predominantly women. The market is forecasted to grow substantially, from $7.68 billion in 2024 to $12.64 billion in 2028.
Coeptis Therapeutics is developing a portfolio of cell therapy platforms for cancer, autoimmune, and infectious diseases, featuring licensed assets from Deverra Therapeutics and the University of Pittsburgh, as well as collaborations with VyGen-Bio and the Karolinska Institutet.
The press release includes forward-looking statements involving risks and uncertainties, including the potential inability to realize the anticipated benefits of the licensed assets, the risks of clinical trial failures, and the impact of the global COVID-19 pandemic.
The information in this article is based on a press release statement from Coeptis Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
